Lilly Expects Zyprexa Sales To Flatten During Bristol Abilify Launch In Q4
Executive Summary
Lilly is preparing for a temporary slowdown in Zyprexa growth during the introduction of Bristol-Myers Squibb's schizophrenia drug Abilify
You may also be interested in...
Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says
The impact of Texas Medicaid's decision to require prior authorization for Zyprexa will stabilize after about six months, Lilly Investor Relations Manager Heidi Straub said April 19
Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says
The impact of Texas Medicaid's decision to require prior authorization for Zyprexa will stabilize after about six months, Lilly Investor Relations Manager Heidi Straub said April 19
FDA Sides With Lilly; Seeks Class Warning On Antipsychotic Diabetes Risk
The comparative risk for diabetes among atypical antipsychotics needs further research, FDA says in a letter to six manufacturers requesting a diabetes and hyperglycemia warning across the class